Business Context and Reporting Period
Company: Kiniksa Pharmaceuticals International, Plc (KNSA)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Kiniksa is a biopharmaceutical company focused on cardiovascular indications. Its primary commercial product is ARCALYST (rilonacept), approved for recurrent pericarditis, Cryopyrin-Associated Periodic Syndromes (CAPS), and Deficiency of Interleukin-1 Receptor Antagonist (DIRA). The company is advancing a pipeline including KPL-387 (Phase 2/3 for recurrent pericarditis) and KPL-1161 (pre-clinical). In 2025, the company completed a redomiciliation from Bermuda to the United Kingdom.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $677.6 million | $423.2 million | +60% |
| Product Revenue (Net) | $677.6 million | $417.0 million | +62% |
| License & Collaboration Revenue | $0 | $6.2 million | -100% |
| Net Income (Loss) | $59.0 million | ($43.2 million) | Turnaround to Profit |
| Operating Income | $77.2 million | ($45.6 million) | Turnaround to Profit |
| Cash & Equivalents | $165.6 million | $183.6 million | -10% |
| Short-Term Investments | $248.5 million | $60.0 million | +314% |
| Total Liquidity | $414.1 million | $243.6 million | +70% |
Note: The filing text does not provide a specific gross margin percentage, but Cost of Goods Sold was $77.7 million against $677.6 million in product revenue.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 60% year-over-year, driven primarily by a 62% increase in ARCALYST product sales due to higher patient enrollment.
- Profitability: The company achieved a net income of $59.0 million in 2025, reversing a net loss of $43.2 million in 2024. Operating income turned positive at $77.2 million.
- Expense Shifts:
- Collaboration Expenses: Increased 79% to $229.5 million, primarily due to the profit-sharing agreement with Regeneron on increased ARCALYST sales.
- R&D Expenses: Decreased 13% to $96.9 million. This was driven by a 90% reduction in Abiprubart expenses (following discontinuation of the Sjögren's Disease trial) and wind-down of Vixarelimab, partially offset by a 321% increase in KPL-387 expenses due to Phase 2/3 trial initiation.
- SG&A Expenses: Increased 17% to $196.3 million, largely due to increased headcount and sales/marketing expansion.
- Liquidity: Total cash, cash equivalents, and short-term investments grew to $414.1 million, reflecting strong operating cash flow of $138.0 million.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- ARCALYST: Management expects continued growth driven by disease awareness and earlier prescription in the recurrent pericarditis market. A collaborative study with The Mayo Clinic on cardiac sarcoidosis was initiated in late 2024.
- KPL-387: Phase 2 dose-focusing data is expected in the second half of 2026. The FDA granted Orphan Drug Designation in October 2025.
- KPL-1161: Pre-clinical activities are ongoing, with a Phase 1 first-in-human trial expected by the end of 2026.
- Abiprubart: Development in Sjögren's Disease was discontinued in February 2025; the company is exploring strategic alternatives for the asset.
- Manufacturing: The company is in the process of transferring ARCALYST drug substance manufacturing from Regeneron to Samsung Biologics. This transfer is subject to regulatory approval and carries execution risks.
Key Risks and Contingencies
- Manufacturing Transfer: Significant risk associated with the technology transfer of ARCALYST to Samsung Biologics. Delays or failure to qualify the new facility could impact supply.
- Regulatory & Pricing: Potential impact of U.S. healthcare legislation (Inflation Reduction Act) and executive orders on drug pricing and reimbursement. Tariffs on imported pharmaceutical products could increase costs post-transfer.
- Competition: Emerging competitors in recurrent pericarditis (e.g., Ventyx Biosciences, Cardiol Therapeutics) and potential biosimilar competition once exclusivity periods lapse.
- Concentration of Ownership: A multi-class share structure gives significant voting control to executive officers and directors, potentially limiting shareholder influence.
Investor Verification Checklist
- Manufacturing Timeline: Verify the status and regulatory approval timeline for the ARCALYST technology transfer to Samsung Biologics to ensure no supply disruptions.
- KPL-387 Trial Data: Monitor the expected Phase 2 data release in H2 2026 for efficacy and safety signals that will dictate future development strategy.
- Regulatory Pricing Impact: Assess the potential financial impact of new U.S. executive orders on drug pricing and the Inflation Reduction Act on ARCALYST net revenue.
- Strategic Alternatives for Abiprubart: Track progress on potential out-licensing or partnership deals for the Abiprubart asset to realize value from the discontinued program.
- Profit Sharing Mechanics: Review the specific cost deductions in the Regeneron profit-sharing agreement to understand the margin impact on future ARCALYST revenue growth.